Chill bro, there is no such thing as safe yet rewarding stock. if want safe investment can't expect so much from this stocks, there is much more outside to choose from
Consider health care stocks. For those investors looking to emphasize less economically sensitive parts of the market, I continue to prefer health care, which historically has been less sensitive to rising rates than other traditionally defensive sectors.
After turning over from a Pn 17 company, hovid is in a steady growth phase. I collect hovid bcos I am very impressed by the spirit in R & D and effort in turning a family based business into a pharmaceutical company.
Samy2015, haha..ya, invested in Hovid/Hovid Wb too. Aldy play quite some round here, so far so good for Hovid, steady strong enough. Just the matter of time for it to breakthrough higher point.
The Malaysian healthcare system relies heavily on generic medicines. The more new medicine that enters the Malaysian market after signing the TPPA the more varieties of generic medicines there will be once the patent protection term expires.
There are currently over 40 local generic manufacturers in Malaysia that are capable of producing at least 80% of the drugs in the Malaysian National Essential Drug List. Most of the drugs produced cater to domestic consumption.
Moving forward, Ho says he sees opportunities in the RM422bil of prescription and pharmaceutical drug patents that are set to expire in the next 10 years. "
"This meant Malaysia would be going from zero patent protection for biologics medicines here, to a five-plus-three year period. “We are moving from zero to eight, which means the generic version can only appear after the eighth year"
MD from Hovid: “Say if a company files in the year 2000 but the patent is only approved in 2007 - so the clock starts ticking from 2007 not the year 2000. The additional seven years incurred is because we were late to approve the patent,” Ho says.
“This is why we hope the Government can review the patenting process to ensure the country is competitive because if the process is delayed, then the generic version that will be manufactured here will also be delayed.
“And the missed opportunity makes us lose our competitive advantage as other countries can manufacture the generic drug earlier,” he adds.
Unefficient of patenting process + TPPA impact to government procurement policy...may put our local companies at risk.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Shacks
1,542 posts
Posted by Shacks > 2015-09-08 15:57 | Report Abuse
It's just where they wan the resistance to be.